Physician profile
Howard B Abromowitz
NPI 1508812546
$845.02
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $118 · 2021: $89.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $188.70 | 2019-2020 | |
| Boston Scientific Corporation | $126.16 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $121.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| 180 Medical, INC. | $61.58 | 2019 | |
| Medtronic USA, INC. | $49.44 | 2019 | |
| Janssen Biotech, INC. | $44.67 | 2019 | |
| Abbvie INC. | $29.12 | 2019 | |
| Aytu Biopharma, INC. | $24.17 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $21.15 | 2019 | |
| Amgen INC. | $18.73 | 2019 | |
| Neotract INC. | $18.07 | 2019 | |
| Genzyme Corporation | $16.81 | 2019 | |
| Coloplast Corp | $13.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Abromowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.